BioSig Technologies Retains Gilmartin Group for Investor Relations
September 24 2018 - 8:00AM
BioSig Technologies, Inc. (NASDAQ:BSGM), a medical device company
developing a proprietary biomedical signal processing platform
designed to address an unmet technology need for the $4.6 billion
electrophysiology (EP) marketplace, announced today that it has
retained Gilmartin Group for strategic investor relations and
communication services.
“We are delighted to engage the team at Gilmartin Group as
investor relations advisors. BioSig places a high priority on
shareholder value and I am confident that Gilmartin’s extensive
experience in capital markets, combined with their deep expertise
in the healthcare technology sector makes them an ideal partner as
we seek to raise visibility of BioSig within the investment
community,” stated Mr. Kenneth Londoner, Chairman and CEO of BioSig
Technologies.
"This is a very exciting time for us. We have built a strong
balance sheet, world-class IP, a leadership team with deep clinical
and commercial expertise, and the support of several leading
medical centers of excellence. Now with the recent FDA clearance of
our PURE EP™ System and the commencement of trading on the Nasdaq
stock exchange, we feel it appropriate to elevate and bolster our
investor relations program and look forward to partnering with the
team at Gilmartin IR,” added Londoner.
About BioSig Technologies BioSig Technologies
is a medical technology company developing a proprietary biomedical
signal processing platform designed to improve the $4.6 billion
electrophysiology (EP) marketplace (www.biosigtech.com). Led by a
proven management team and a veteran, independent Board of
Directors, Los Angeles-based BioSig Technologies is preparing to
commercialize its PURE EP™ System. The technology has been
developed to address an unmet need in a large and growing
market.
The Company’s first product, PURE EP™ System, is a novel cardiac
signal acquisition and display system which is engineered to assist
electrophysiologists in clinical decision-making during procedures
to diagnose and treat patients with abnormal heart rates and
rhythms. BioSig’s main goal is to deliver technology to improve
upon catheter ablation treatments for the prevalent and potentially
deadly arrhythmias, Atrial Fibrillation and Ventricular
Tachycardia. BioSig has partnered with Minnetronix on technology
development and has received FDA 510(k) clearance for its PURE EP™
System.
About Gilmartin GroupGilmartin Group is a
strategic advisory firm that provides comprehensive service
offerings throughout the lifespan of its client companies.
The team at Gilmartin has deep experience in Capital Markets,
Investor Relations, Corporate Communications and Business
Development / Strategic Advisory services. The firm’s professionals
have spent their careers on Wall Street with backgrounds in Equity
Research, Investment Banking and Equity Capital Markets. They bring
that experience and expertise to clients to create durable
shareholder value. More information can be found on the company’s
website at http://gilmartinir.com/clients/.
Contact:
Natasha Drapeau
BioSig Technologies, Inc.
Executive Vice President
12600 Hill Country Blvd R-275
Austin, TX 78738
nrusskina@biosigtech.com
512-329-2643
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Sep 2023 to Sep 2024